TriangleNCT01208103 · OUTCOME
To Determine the Overall PFS for CAPOX and Bevacizumab
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 39 months
What was measured
Time interval in months from date of first treatment until the date of first documented progression
Groups in this outcome
Bevacizumab + Capecitabine + Oxaliplatin
Capecitabine 750mg/m2 oral twice daily, Days 1 - 14 and Bevacizumab 7.5 mg/kg IV over 90 minutes on Day 1 and Oxaliplatin 130 mg/m2 IV over 2 hours Day 1 of 21-day cycle.
| Group | Source count |
|---|---|
| Bevacizumab + Capecitabine + Oxaliplatin | 30 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Bevacizumab + Capecitabine + Oxaliplatin | 8.7 | Not reported | 4.9 | 10.5 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 4.9
- upper Limit
- 10.5
- value
- 8.7
- denoms
- counts
- group Id
- OG000
- value
- 30
- units
- Participants
- description
- Time interval in months from date of first treatment until the date of first documented progression
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Capecitabine 750mg/m2 oral twice daily, Days 1 - 14 and Bevacizumab 7.5 mg/kg IV over 90 minutes on Day 1 and Oxaliplatin 130 mg/m2 IV over 2 hours Day 1 of 21-day cycle.
- id
- OG000
- title
- Bevacizumab + Capecitabine + Oxaliplatin
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- 39 months
- title
- To Determine the Overall PFS for CAPOX and Bevacizumab
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice